Диссертация (Роль системы комплемента в развитии патологии почек у больных с микроангиопатическими синдромами), страница 25
Описание файла
Файл "Диссертация" внутри архива находится в папке "Роль системы комплемента в развитии патологии почек у больных с микроангиопатическими синдромами". PDF-файл из архива "Роль системы комплемента в развитии патологии почек у больных с микроангиопатическими синдромами", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата медицинских наук.
Просмотр PDF-файла онлайн
Текст 25 страницы из PDF
2010. (36). C. 620–624.102. Peerschke E.I., Yin W., Ghebrehiwet B. Complement activation onplatelets: Implications for vascular inflammation and thrombosis //Molecular Immunology. 2010. № 13 (47). C. 2170–2175.103. Pettigrew H.D., Teuber S.S., Gershwin M.E. Clinical significance ofcomplement deficiencies // 2009.104.
Picard C, Burtey S B.C. Pathophysiology and treatment of typicaland atypical hemolytic uremic syndrome // Pathologie Biologie. 2015.(63). C. 136–43.105. Pierangeli S., Bertolaccini M.L., Khamashta M. Catastrophicantiphospholipid syndrome (CAPS): update from the ‘CAPS Registry’ //Lupus. 2010. № 4 (19). C.
412–418.149106. Pierangeli S.S. [и др.]. Toll-like receptor and antiphos-pholipidmediated thrombosis: in vivo studies // Ann Rheum Dis. 2007. (66).107. Pierangelli S.S., Vega-Ostertag M.E., E. R. Toll-like receptor andantiphospholipid thrombosis: in vivo studies // Ann Rheum Dis.
2007.(66). C. 1327–1333.108. Redecha P. [и др.]. Tissue factor: a link between C5a and neutrophilactivation in antiphospholipid antibody induced fetal injury // Blood.2007. (110).109. Richards A. [и др.]. Implications of the initial mutations inmembrane cofactor protein (MCP; CD46) leading to atypical hemolyticuremic syndrome // Mol Immunol. 2007. (44).110. Ricklin D. [и др.]. Complement: a key system for immunesurveillance and homeostasis. // Nature immunology. 2010. № 9 (11).
C.785–97.111. Ridolfi R., Hutchins G., Bell W. The heart and cardiac conductionsystem in thrombotic thrombocytopenic purpura: A clinicopathologicstudy of 17 autopsied patients // Annals of Internal Medicine. 1979. № 3(91). C. 357–363.112. Rittirsch D., Klos A., Gebhard F. Interaction Between theCoagulation and Complement System NIH Public Access 2008. №February.113. Rodríguez-pintó I.
[и др.]. What is the best strategy in treatingcatastrophic antiphospholipid syndrome ? // International Journal ofClinical Rheumatology. 2015. № 4 (10). C. 245–55.114. Rodríguez-pintó I. [и др.]. Catastrophic antiphospholipid syndrome( CAPS ): Descriptive analysis of 500 patients from the InternationalCAPS Registry Catastrophic antiphospholipid syndrome ( CAPS ):Descriptive analysis of // Autoimmunity Reviews.
2016. № September.115. Rodríguez-Pintó I. [и др.]. Catastrophic antiphospholipid syndrome150(CAPS): Descriptive analysis of 500 patients from the InternationalCAPS Registry // Autoimmunity Reviews. 2016.116. Romay-Penabad Z. [и др.]. C5a Receptor-Deficient Mice AreProtected from Thrombophilia and Endothelial Cell Activation Inducedby Some Antiphospholipid Antibodies // Annals of the New YorkAcademy of Sciences. 2007. № 1 (1108).
C. 554–566.117. Roumenina L., Loirat C., Dragon-Durey M.-A. Alternativecomplement pathway assessment in patients with atypical HUS // Journalof Immunological Methods. 2011. № 5(1-2) (36). C. 8–26.118. Rubino S., Cappuccinelli P., Kelvin D.J. Outbreak Escherichia coli (STEC ) serotype O104 outbreak causing haemolytic syndrome ( HUS ) inGermany and France 2011. C.
8–11.119. Saadi S. [и др.]. Complement-mediated regulation of tissue factoractivity in endothelium. // The Journal of Experimental Medicine. 1995.№ 6 (182). C. 1807 LP-1814.120. Sallée M. [и др.]. Myocardial infarction is a complication of factorH-associated atypical HUS // Nephrology Dialysis Transplantation.
2010.№ 6 (25). C. 2028–2032.121. Salmon J., Girardi G. (ed): .Curr Dir Autoimmun. , 2004, vol 7, ppпод ред. G. Tsokos, KARGER, 2003. 133–148 с.122. Salvadori M., Bertoni E. Update on hemolytic uremic syndrome:diagnostic and therapeutic recommendations. // World J Nephrol. 2013.(2(3)). C. 56–7.123. Scheiring J, Andreoli SP Z.L. Treatment and outcome of Shigatoxin-associated hemolytic uremic syndrome (HUS) // PediatricNephrology. 2008. № 10 (23).
C. 1749–60.124. Schramm E.C. [и др.]. Functional mapping of the interactionsbetween complement C3 and regulatory proteins using atypical hemolyticuremic syndrome-associated mutations. // Blood. 2015. № 15 (125). C.1512359–2370.125. Schreiber A. [и др.]. Alternative Complement Pathway in thePathogenesis of Disease Mediated by Anti- Neutrophil Cytoplasmic ...Alternative Complement Pathway in the Pathogenesis of DiseaseMediated by Anti- Neutrophil Cytoplasmic Autoantibodies 2007. №March 2014.126. Sellier-Leclerc A.-L.
[и др.]. Differential impact of complementmutations on clinical characteristics in atypical hemolytic uremicsyndrome. // Journal of the American Society of Nephrology : JASN.2007. № 8 (18). C. 2392–400.127. Servais A. [и др.]. Primary glomerulonephritis with isolated C3deposits: a new entity which shares common genetic risk factors withhaemolytic uraemic syndrome // J Med Genet.
2007. (44).128. Shinzato M.M., Bueno C., Viana V. Complement-fixing activity ofanticardiolipin antibodies in patients with and without thrombosis //Lupus. 2005. № 12 (14). C. 953–958.129. Ståhl A. [и др.]. Factor H dysfunction in patients with atypicalhemolytic uremic syndrome contributes to complement deposition onplatelets and their activation // Blood.
2008. № 11 (111). C. 5307 LP5315.130. Steinborn M. [и др.]. CT and MRI in haemolytic uraemic syndromewith central nervous system involvement: distribution of lesions andprognostic value of imaging findings // Pediatric Radiology. 2004. № 10(34). C. 805–810.131. Stühlinger W, Kourilsky O, Kanfer A S.J. Haemolytic-uraemicsyndrome: evidence for intravascular C3 activation // Lancet. 1974.
(2).C. 788–9.132. Swisher K.K. [и др.]. Pancreatitis preceding acute episodes ofthrombotic thrombocytopenic purpura-hemolytic uremic syndrome:152report of five patients with a systematic review of published reports //Haematologica. 2007. № 7 (92). C. 936 LP-943.133. Taylor CM. Enterohaemorrhagic Escherichia coli and Shigelladysenteriae type 1- induced haemolytic uraemic syndrome // PediatrNephrol.
2008. (23). C. 1425–1431.134. Tektonidou M.G. [и др.]. Antiphospholipid syndrome nephropathyin patients with systemic lupus erythematosus and antiphospholipidantibodies: Prevalence, clinical associations, and long-term outcome //Arthritis & Rheumatism. 2004. № 8 (50). C. 2569–2579.135. Thompson RA W.M. Hypocomplementaemia due to a geneticdeficiency of beta 1H globulin. // Clin Exp Immunol. 1981. (46). C. 110–9.136. Venables J. [и др.]. Atypical Haemolytic Uraemic SyndromeAssociated with a Hybrid Complement Gene // PLoS Med. 2006. № 10(3).
C. 1957–67.137. Warwicker P, Goodship TH, Donne RL et al. G. Genetic studiesinto inherited and sporadic hemolytic uremic syndrome. // Kidney Int1998;53:836-44. 1998. (53). C. 836–44.138. Westra D. [и др.]. Serological and genetic complement alterations ininfection-induced and complement-mediated hemolytic uremic syndrome// Pediatric Nephrology. 2016. № 2 (32). C.
297–309.139. Yamamoto H. [и др.]. Numerous Small Vegetations RevealingLibman-Sacks Endocarditis in Catastrophic Antiphospholipid Syndrome// Circulation. 2007. № 20 (116). C. e531 LP-e535.140. Zaid G., Dawod S., Rosenschein U. Immune thrombocytopenicPurpura and myocardial infarction: A dilemma of management // IsraelMedical Association Journal. 2013. № 12 (15). C. 775–776.141. Zhang T.
[и др.]. Comprehensive analysis of complement genes inpatients with atypical hemolytic uremic syndrome // American Journal of153Nephrology. 2016. № 3 (43). C. 160–169.154.
